Published on
Jul 9, 2025
SUPRAME Trial Seeks to Establish IMA203 as the First TCR-Based Therapy for Cutaneous Melanoma
Positive safety and efficacy findings with the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in patients with PD-1 inhibitor–refractory metastatic melanoma from the phase 1 ACTengine trial (NCT03686124) have propelled the launch of the phase 3 …
Source:
OncLive
-
Pending
